American College of Clinical Pharmacy
      Search      Cart

Perioperative Care PRN Focus Session -- Red Light...Green Light...Red Light: Anticoagulation Challenges in the Surgical Patient

Sunday, October 27, 2019 from 2:15 PM to 3:45 PM EST at 3rd Floor: Rendezvous Trianon

Available for 1.50 hours of CPE credit
Activity Number: 0217-0000-19-178-L01-P
Activity Type: An Application-Based Activity

  • Eric Johnson, Pharm.D., BCCCPModerator: Eric Johnson, Pharm.D., BCCCP
    Perioperative Critical Care Pharmacist, University of Kentucky HealthCare, Lexington, KY
      View Biography

Re-doing the Undo: Resuming Oral Anticoagulation following Emergent Perioperative Reversal
2:15 PM

  • Audrey  Littlefield, Pharm.D.Speaker: Audrey Littlefield, Pharm.D.
    Clinical Pharmacy Manager, Cardiothoracic ICU at NewYork-Presbyterian Hospital, Weill Cornell Medical Center
      View Biography

Learning Objectives
1. Identify potential barriers to resuming oral anticoagulation following emergent reversal.
2. Evaluate surgical considerations for resuming oral anticoagulation following emergent reversal.
3. Describe patient specific risks and benefits associated with resuming oral anticoagulation following emergent reversal.
HIT-ing the Wall: Perioperative Management of Heparin-Induced Thrombocytopenia
2:45 PM

  • James S. Kalus, Pharm.D., BCPSSpeaker: James S. Kalus, Pharm.D., BCPS
    James S. Kalus, Pharm.D., FASHP Director of Pharmacy Henry Ford Health System Detroit, Michigan
      View Biography

Learning Objectives
1. Review the diagnosis, sequela and clinical duration of Heparin-Induced Thrombocytopenia.
2. Identify appropriate heparin-alternatives in patients that require intraoperative anticoagulation.
3. Describe potential adjunctive therapies that enable perioperative heparin use in patients with suspected HIT.
Controlling Cost Hemorrhage: Pharmacoeconomic Mitigations of Cardiac Surgery
3:15 PM

  • Speaker: Aaron J. Roberts, Pharm.D., BCPS
    UC Davis Health, Pharmacy Department, Sacramento, Calfornia

Learning Objectives
1. Compare evidence, efficacy and dosing option of lysine antagonists for hemostatic control during cardiac, thoracic or vascular surgery.
2. Identify recombinant and endogenous coagulation products available for intraoperative use in the coagulopathic surgical patients.
3. Define the role clinical pharmacists can play in establishing use criteria for perioperative hemostatics.